(AOF) – Eurofins has announced the launch of a new screening tool for the B.1.1.529 variant. The GSD NovaType Select is a set of RT-PCR tests that specifically detect mutations in the SARS-CoV-2 genome in about 1 hour, much faster than genome sequencing methods. It can thus differentiate the B.1.1.529 variant from the currently dominant Delta variant and can be used as a large-scale screening test.
Additionally, all samples positive for the P681H mutation can be tested with GSD NovaType Select T478K and K417N to further differentiate B.1.1.529 from other circulating SARS-CoV-2 variants, the lab explains.
The AOF information reproduced on Capital.fr is taken from the AOF information service. This information is protected by intellectual property rights owned by OPTION FINANCE SAS, publisher of the AOF real-time stock market information service, and its contributors. Consequently, any reproduction, copy, duplication, modification, transfer, redistribution, translation, commercial or non-commercial exploitation, creation of hypertext link or reuse in any way whatsoever of this information is subject to the prior written consent of OPTION FINANCE SAS and its contributors. AOF can be reached at the following address [email protected] OPTION FINANCE SAS collects its data from sources it considers the most reliable. However, subject to gross negligence, OPTION FINANCES SAS and its contributors in no way guarantee the absence of errors and defects, even hidden, nor the exhaustiveness or lack of conformity for any use whatsoever of these data and of OPTION FINANCE. SAS or one of its contributors, and cannot be held responsible for delays or interruptions that could affect access to them. The user of the OPTION FINANCE SAS service will use AOF data at his own risk and must hold OPTION FINANCE SAS and its contributors harmless from any claim resulting from this use.
Receive our latest news
Every morning, the information to remember about financial markets.